Results 21 to 30 of about 400 (179)

Е-кадеринот и неговата улога кај пациентки Ñо Ñерозен оваријален карцином во напреднат Ñтадиум [PDF]

open access: yes, 2017
Ovarian cancer is the fifth leading cause of cancer deaths and has the highest mortality rate among gynecologic cancers in women in North America and Europe.The aim of this study wasto analyze the correlation between E-cadherin expression and clinical ...
ÐлулоÑки, Игор
core   +1 more source

YAP1::TFE3 mediates endothelial‐to‐mesenchymal plasticity in epithelioid hemangioendothelioma

open access: yesMolecular Oncology, EarlyView.
The YAP1::TFE3 fusion protein drives endothelial‐to‐mesenchymal transition (EndMT) plasticity, resulting in the loss of endothelial characteristics and gain of mesenchymal‐like properties, including resistance to anoikis, increased migratory capacity, and loss of contact growth inhibition in endothelial cells.
Ant Murphy   +9 more
wiley   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon   +13 more
wiley   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

open access: yesMolecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang   +3 more
wiley   +1 more source

ТранÑпериотонеална радикална нефректомија во третманот на карциномот на бубрег: компликации [PDF]

open access: yes, 2016
Ðаnравен е преглед на наашето хируршко иÑкуÑтво Ñо интра и поÑтоnеративните компликации, документирано кај 275 паци­ÐµÐ½Ñ‚и Ñо карциноми на бубрег
ПетровÑки, Д   +1 more
core   +1 more source

ATG4B is required for mTORC1‐mediated anabolic activity and is associated with clinical outcomes in non‐small cell lung cancer

open access: yesFEBS Open Bio, EarlyView.
The relationship between anabolic and catabolic processes governing lung cancer cell growth is nuanced. We show that ATG4B, an autophagy regulator, is elevated in lung cancer and that high ATG4B is associated with worse patient outcomes. Targeting ATG4B in cells reduces growth, protein synthesis, and mTORC1 activity, demonstrating a new relationship ...
Patrick J. Ryan   +6 more
wiley   +1 more source

ПРИСТÐП ДО БЕЗБЕДÐРВОДРЗРПИЕЊЕ ВО СЕВЕРОИСТОЧÐИОТ РЕГИОРÐРРЕПУБЛИКРМÐКЕДОÐИЈÐ- РЕТРОСПЕКТИВÐÐ ÐÐÐЛИЗР[PDF]

open access: yes, 2017
СeвероиÑточниот Регион на Република Македонија, Ñо површина од 2310 км2, го Ñочинуваат опш- тините Куманово, Старо Ðагоричино, Кратово, Ранковце,
КочубовÑки, Михаил   +2 more
core   +1 more source

Plasma Proteomic Signatures for Alzheimer's Disease: Comparable Accuracy to ATN Biomarkers and Cross‐Platform Validation

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background There is growing recognition of the potential of plasma proteomics for Alzheimer's Disease (AD) risk assessment and disease characterization. However, differences between proteomics platforms introduce uncertainties regarding cross‐platform applicability.
Manyue Hu   +9 more
wiley   +1 more source

ЕВÐЛУÐЦИЈРÐРПРОГРÐМИТЕ ЗРПРЕВЕÐЦИЈРÐРМÐЛИГÐИ ÐЕОПЛÐЗМИ ВО РЕПУБЛИКРМÐКЕДОÐИЈР(2005-2015) [PDF]

open access: yes, 2017
БолеÑти на Ñовремениот живот и водечка причина за морбидитет и морталитет во Република Македонија и во Ñветот Ñе хроничните незаразни болеÑÑ‚
СпаÑовÑки, Моме   +1 more
core   +1 more source

Home - About - Disclaimer - Privacy